Uncategorized

Lacerta Therapeutics Expands Executive Leadership Team

ALACHUA, Fla.–(BUSINESS WIRE)–Lacerta Therapeutics, a preclinical-stage gene therapy company, announces an expansion in the executive leadership team: Kenneth Warrington, Jr., PhD, co-founder of Lacerta, has joined as the company’s Chief Technology Officer (CTO), and Darin Falk, PhD, former Vice President of Gene Therapy Programs at Lacerta, will now serve as the company’s Chief Scientific Officer …

Lacerta Therapeutics Expands Executive Leadership Team Read More »

GrowFL Announces Lacerta Therapeutics as an Honoree: 11th Annual Florida Companies to Watch

ALACHUA, Fla.–(BUSINESS WIRE)–Lacerta Therapeutics is pleased to be among the top 50 second-stage companies in Florida selected as an 11th Annual GrowFL Florida Companies to Watch honoree, a statewide competition that identifies companies expected to see significant growth over the next several years. The 11th Annual GrowFL Florida Companies to Watch awards celebration is sponsored …

GrowFL Announces Lacerta Therapeutics as an Honoree: 11th Annual Florida Companies to Watch Read More »

Lacerta Therapeutics Appoints Min Wang, PhD, JD and Marc Wolff to its Board of Directors

ALACHUA, Fla.–(BUSINESS WIRE)–Lacerta Therapeutics, Inc. a gene therapy company dedicated to the discovery and development of AAV-based gene therapies, appoints Min Wang, PhD, JD and Marc Wolff to its Board of Directors. Dr. Min Wang has over 20 years of experience in the biotech space where she has operated as a business and legal advisor …

Lacerta Therapeutics Appoints Min Wang, PhD, JD and Marc Wolff to its Board of Directors Read More »

LACERTA THERAPEUTICS FEATURED AT ALACHUA CHAMBER LUNCH

We want to thank the Alachua Chamber of Commerce for featuring us at the Alachua Chamber Lunch on August 3rd, 2021 at the Alachua Woman’s Club! Dr. Edgar Rodriguez-Lebron and Dr. Jackson Streeter presented a well-rounded introduction of our company and upcoming biotechnology endeavors. We look forward to continuing collaborations with the City of Alachua …

LACERTA THERAPEUTICS FEATURED AT ALACHUA CHAMBER LUNCH Read More »

UCB strengthens its gene therapy activities with additional pipeline programs, capabilities and platforms

BRUSSELS, Nov. 12, 2020 /PRNewswire/ — UCB today announced the acquisition of Handl Therapeutics BV, a rapidly growing and transformative gene therapy company based in Leuven, Belgium and a new collaboration with Lacerta Therapeutics, a Florida based clinical stage gene therapy company. The new acquisition and collaboration will together serve to rapidly accelerate UCB’s ambition in gene therapy. UCB has a vision …

UCB strengthens its gene therapy activities with additional pipeline programs, capabilities and platforms Read More »

Lacerta Therapeutics Signs Gene Therapy Research Partnership with UCB

New research collaboration and licensing agreement with Lacerta provides UCB access to a novel gene therapy program and proprietary AAV capsids ALACHUA, Fla., November 12, 2020 (Newswire.com) – Lacerta Therapeutics today announced a new gene therapy research collaboration with UCB, a global biopharmaceutical company. The research collaboration and licensing agreement with UCB will focus on a …

Lacerta Therapeutics Signs Gene Therapy Research Partnership with UCB Read More »

Concept Companies Unveils New Office for Lacerta Therapeutics in Alachua’s Copeland Park

Link to article ALACHUA, Fla., Oct. 8, 2020 /PRNewswire/ — Gainesville-based developer Concept Companies has completed construction on a new 12,950-square-foot office and lab building in Copeland Park for Lacerta Therapeutics, a clinical-stage gene therapy company. Lacerta Therapeutics’ new office space is located in Copeland Park, a biotechnology and life science research community in Alachua, Florida. With its …

Concept Companies Unveils New Office for Lacerta Therapeutics in Alachua’s Copeland Park Read More »

Gene therapy startup Lacerta Therapeutics raises $30M in equity financing from Sarepta

Sarepta Therapeutics gains rights to University of Florida-resident startup’s programs for central nervous system diseases. By Alaric DeArment August 14, 2018  – A startup based out of the University of Florida developing viral vector-based gene therapies has drawn an equity investment from a larger, commercial-stage drugmaker. Lacerta Therapeutics closed on the $30 million investment round, made …

Gene therapy startup Lacerta Therapeutics raises $30M in equity financing from Sarepta Read More »

UF Innovate | Sid Martin Biotech Resident Company Lacerta Therapeutics, Inc. Closes On $30 million Investment Round

GAINESVILLE, Fla.–(BUSINESS WIRE)–UF Innovate | Sid Martin Biotech, the leading biotechnology incubator at the University of Florida, announces resident company Lacerta Therapeutics, Inc., has closed on a $30 million investment round. Lacerta is a clinical-stage gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop treatments for central nervous system and …

UF Innovate | Sid Martin Biotech Resident Company Lacerta Therapeutics, Inc. Closes On $30 million Investment Round Read More »

Sarepta Therapeutics Signs Long-term Strategic Investment and License Agreements with Lacerta Therapeutics

Press Release August 8, 2018 at 4:01 PM EDT Sarepta Therapeutics Signs Long-term Strategic Investment and License Agreements with Lacerta Therapeutics, Gaining Rights to Multiple CNS-targeted Gene Therapy programs and Access to Important Gene Therapy Talent and Tools — Sarepta expands its presence in gene therapy and broadens its reach with license to up to …

Sarepta Therapeutics Signs Long-term Strategic Investment and License Agreements with Lacerta Therapeutics Read More »